TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
NRXP

NRX Pharmaceuticals Inc

Healthcare · Biotechnology

3.40$ +1.2% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns NRX Pharmaceuticals Inc (NRXP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.4% of the shares are freely tradable; institutional investors hold 17.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 17.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 7.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 86.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 22.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 43Mio.

Largest Shareholders

Institutions

Institutions NRXP
Name Stake (%) Shares Change (%) Date
B Group, Inc 6.93 3,000,000 +0.0 03/31/2026
Vanguard Capital Management, LLC 2.68 1,160,184 +0.0 03/31/2026
Citadel Advisors Llc 1.57 680,043 +0.0 06/30/2026
AdvisorShares Investments, LLC 1.52 659,018 +56.7 06/30/2026
Commonwealth Equity Services, LLC 1.05 454,418 +14.3 06/30/2026
Geode Capital Management, LLC 0.72 310,112 +41.7 03/31/2026
Vanguard Fiduciary Trust Co 0.39 169,580 +0.0 03/31/2026

Funds

Funds NRXP
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.93 1,267,102 +0.0 07/31/2026
AdvisorShares Psychedelics ETF 1.73 750,016 +0.0 08/31/2026
Vanguard Institutional Extnd Mkt Idx Tr 0.73 313,881 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?